Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Non-Current Debt: 2010-2020

Historic Non-Current Debt for Anika Therapeutics (ANIK) over the last 3 years, with Sep 2020 value amounting to $25.0 million.

  • Anika Therapeutics' Non-Current Debt was N/A to $25.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was $25.0 million, marking a year-over-year change of. This contributed to the annual value of $8.0 million for FY2012, which is 16.67% down from last year.
  • Latest data reveals that Anika Therapeutics reported Non-Current Debt of $25.0 million as of Q3 2020, which was down 50.00% from $50.0 million recorded in Q2 2020.
  • Anika Therapeutics' Non-Current Debt's 5-year high stood at $50.0 million during Q2 2020, with a 5-year trough of $25.0 million in Q3 2020.
  • For the 1-year period, Anika Therapeutics' Non-Current Debt averaged around $37.5 million, with its median value being $37.5 million (2020).